Correction: Patient eligibility for trials with imaging response assessment at the time of molecular tumor board presentation.

IF 3.5 2区医学 Q2 ONCOLOGY

Cancer Imaging Pub Date : 2024-07-01 DOI:10.1186/s40644-024-00724-5

Nabeel Mansour, Kathrin Heinrich, Danmei Zhang, Michael Winkelmann, Maria Ingenerf, Lukas Gold, Konstantin Klambauer, Martina Rudelius, Frederick Klauschen, Michael von Bergwelt-Baildon, Jens Ricke, Volker Heinemann, C Benedikt Westphalen, Wolfgang G Kunz

引用次数: 0

查看原文本刊更多论文

更正：在肿瘤分子委员会报告时进行影像反应评估的试验患者资格。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Imaging ONCOLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

CiteScore

7.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Cancer Imaging is an open access, peer-reviewed journal publishing original articles, reviews and editorials written by expert international radiologists working in oncology. The journal encompasses CT, MR, PET, ultrasound, radionuclide and multimodal imaging in all kinds of malignant tumours, plus new developments, techniques and innovations. Topics of interest include: Breast Imaging Chest Complications of treatment Ear, Nose & Throat Gastrointestinal Hepatobiliary & Pancreatic Imaging biomarkers Interventional Lymphoma Measurement of tumour response Molecular functional imaging Musculoskeletal Neuro oncology Nuclear Medicine Paediatric.